Suppr超能文献

镰状细胞病的经颅多普勒筛查:来自印度卡纳塔克邦一项区域研究的见解

Transcranial Doppler Screening in Sickle Cell Disease: Insights from a Regional Study in Karnataka, India.

作者信息

Sharma Suryanarayana, Aggarwal Pooja, Gowrishankar Meenakshi, Seshadri Tanya, Sharma Vijay K, Ramachandraiah Kishore, Bhat Deepa

机构信息

Department of Neurology, Apollo Hospitals, Bannerghatta Road, Bengaluru, Karnataka, India.

Department of Anatomy, Jagadguru Sri Shivarathreeshwara Medical College, Mysuru, India.

出版信息

Ann Indian Acad Neurol. 2025 Jul 1;28(4):585-589. doi: 10.4103/aian.aian_65_25. Epub 2025 Jun 4.

Abstract

Sickle cell disease (SCD), a hereditary blood disorder in India, disproportionately affects Adivasi communities burdened by socio-economic and systemic inequities. Stroke, a severe complication of SCD, is underexplored in Indian populations, especially among Adivasi groups. This pilot study evaluated the feasibility of transcranial Doppler (TCD) screening in a peripheral healthcare setting in Karnataka, focusing on Adivasi SCD patients. Among 39 participants (27 HbSS, three HbSβ0, nine HbAS) from a hemoglobinopathy registry, none exhibited elevated time-averaged maximum mean (TAMM) velocities, but 73.3% of SCD patients showed unusually low middle cerebral artery (MCA) velocities (<70 cm/s). Significant differences in basilar artery (BA) flow velocities were noted between SCD and sickle cell trait (SCT) patients ( p <0.05), while MCA parameters were comparable. The findings establish baseline TCD velocities and highlight the need for region-specific stroke prevention guidelines tailored to underserved Adivasi populations.

摘要

镰状细胞病(SCD)是印度一种遗传性血液疾病,对受社会经济和系统性不平等困扰的阿迪瓦西社区影响尤为严重。中风是SCD的一种严重并发症,在印度人群中,尤其是阿迪瓦西群体中,对其研究不足。这项试点研究评估了在卡纳塔克邦的外周医疗环境中进行经颅多普勒(TCD)筛查的可行性,重点关注阿迪瓦西SCD患者。在血红蛋白病登记处的39名参与者(27名HbSS、3名HbSβ0、9名HbAS)中,没有一人表现出时间平均最大平均(TAMM)速度升高,但73.3%的SCD患者显示大脑中动脉(MCA)速度异常低(<70 cm/s)。SCD患者和镰状细胞性状(SCT)患者之间的基底动脉(BA)血流速度存在显著差异(p<0.05),而MCA参数具有可比性。这些发现确定了TCD速度基线,并强调需要为服务不足的阿迪瓦西人群制定针对特定地区的中风预防指南。

相似文献

3
Hydroxyurea (hydroxycarbamide) for sickle cell disease.羟基脲(羟脲)治疗镰状细胞病。
Cochrane Database Syst Rev. 2022 Sep 1;9(9):CD002202. doi: 10.1002/14651858.CD002202.pub3.
5
Hydroxyurea (hydroxycarbamide) for sickle cell disease.羟基脲(羟基脲素)用于镰状细胞病。
Cochrane Database Syst Rev. 2017 Apr 20;4(4):CD002202. doi: 10.1002/14651858.CD002202.pub2.
7
Folate supplementation in people with sickle cell disease.镰状细胞病患者的叶酸补充
Cochrane Database Syst Rev. 2018 Mar 16;3(3):CD011130. doi: 10.1002/14651858.CD011130.pub3.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验